Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Operating Expenses (2016 - 2023)

Endonovo Therapeutics has reported Operating Expenses over the past 12 years, most recently at $473490.0 for Q3 2023.

  • Quarterly results put Operating Expenses at $473490.0 for Q3 2023, down 6.0% from a year ago — trailing twelve months through Sep 2023 was $2.9 million (down 9.28% YoY), and the annual figure for FY2022 was $3.4 million, up 48.37%.
  • Operating Expenses for Q3 2023 was $473490.0 at Endonovo Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for ENDV hit a ceiling of $1.8 million in Q2 2022 and a floor of $365249.0 in Q4 2021.
  • Median Operating Expenses over the past 5 years was $648412.0 (2020), compared with a mean of $788193.7.
  • Biggest five-year swings in Operating Expenses: crashed 43.67% in 2021 and later surged 199.92% in 2022.
  • Endonovo Therapeutics' Operating Expenses stood at $831265.0 in 2019, then fell by 22.0% to $648412.0 in 2020, then crashed by 43.67% to $365249.0 in 2021, then surged by 64.18% to $599648.0 in 2022, then fell by 21.04% to $473490.0 in 2023.
  • The last three reported values for Operating Expenses were $473490.0 (Q3 2023), $1.2 million (Q2 2023), and $612834.0 (Q1 2023) per Business Quant data.